Baxter International Inc.

Baxter Healthcare Sa

Leukocare Ag

Rahul Kumar Singh

Paul Jeffrey Sanders

Heinz Gulle

Krishnakumarsinh Hitendrasinh Parmar

Julia Rabas

Stephanie Klunk

Ben Ko

Eva Reinauer

John Barry

Stella Grosso

Disclosed are a fibrinogen solution and a thrombin solution. The fibrinogen solution comprises fibrinogen at a concentration of at least 40 mg/ml, factor XIII, pharmaceutically acceptable additives and water. The dynamic viscosity of the fibrinogen solution measured at 20° C. increases at most by 35% after storing the solution at 20° C. for 30 days. The thrombin solution comprises thrombin, pharmaceutically acceptable additives and water. The thrombin activity decreases at most by 15% after storing the solution at 25° C. for 14 days. Also disclosed is a fibrin sealant kit with a first container comprising the fibrinogen solution and a second container comprising the thrombin solution. Further, methods for preparing a fibrin sealant and methods for treating a wound are disclosed.

Fibrinogen and thrombin solutions for a fibrin sealant and fibrin sealant kit

Polymeric compositions, methods, and delivery devices for inhibiting bleeding are disclosed. The method includes applying a dried material topically to a wound site, where the material may include a cross-linked biologically compatible polymer which forms a hydrogel when exposed to blood and where the material may not include an active agent such as thrombin. A spring-loaded delivery device as described herein may be used to apply the dried material.

Polymeric compositions, delivery devices, and methods

Growing community of inventors

Milwaukee, WI, United States of America

Rahul Kumar Singh